Knee osteoarthritis (OA) accounts for more than 80% of OA disease burden and has doubled in prevalence in the mid-20th century in the U.S. when compared with people who lived during early industrial era (1800s to early 1900s).1 Currently, the diagnostic and treatment armamentaria are limited. Disease progression is measured by joint space narrowing on…
CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…
Canadian Pediatric Rheumatologist Invested into Order of Canada Peter Dent, MD, professor emeritus of pediatrics at McMaster University in Hamilton, Ontario, Canada, was invested into the Order of Canada in May. The Order of Canada is the country’s highest civilian honor. “Dr. Dent has had a substantial positive impact on healthcare, in Hamilton and far…
Relapsing polychondritis (RPC) is a systemic and, in some cases, fatal disease. Dyspnea with findings of small airway disease—even in the absence of the more commonly associated tracheobronchial abnormalities or pathognomonic clinical findings, such as saddle nose and cauliflower ear—may be presenting signs and symptoms of relapsing polychondritis. Below, we present a case demonstrating that…
(Reuters Health)—Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests. After combining data from 81 randomized controlled trials, researchers found no bone benefits from supplementing the vitamin, according to the report in The Lancet Diabetes & Endocrinology, online October 4. “Our results show that…
Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…
Imagine telling a patient “You’re in remission!” and finding out it’s not true. The last thing you want to do is get it wrong clinically and put your patient on an emotional rollercoaster. With large vessel vasculitis (LVV) in particular, physicians struggle to be accurate, to determine if indeed the disease has gone away or…
With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…
Join us virtually in Chicago, as we stream the 2018 ACR Review Course and ACR/ARHP Annual Meeting live. Registration is now open, and the events will take place Oct. 20‒24. Watch the sessions live in real time, chat with other attendees, and participate in question-and-answer sessions when available. You can also enjoy access to the…
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…